Reliability and validity of the CMT neuropathy score as a measure of disability

Neurology

Volumn 64, Issue 7, 2005, Pages 1209-1214

  Shy, Michael E ^a,b   Blake, J ^b,c   Krajewski, K ^a,b   Fuerst, D R ^a   Laura, M ^b,e   Hahn, A F ^d   Li, J ^a   Lewis, R A ^a   Reilly, M ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHARCOT MARIE TOOTH DISEASE NEUROPATHY SCORE; DIAGNOSTIC VALUE; DISABILITY; DISEASE SEVERITY; FEMALE; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVER VARIATION; PRIORITY JOURNAL; RELIABILITY; SCORING SYSTEM; SELF EVALUATION;

EID: 16844381836     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000156517.00615.A3     Document Type: Article

References (16)

1. Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet 1974;6:98-118.
2. Harding AE, Thomas PK. Genetic aspects of hereditary motor and sensory neuropathy (types I and II). J Med Genet 1980;17:329-336.
3. Harding AE, Thomas PK. Distal and scapuloperoneal distributions of muscle involvement occurring within a family with type I hereditary motor and sensory neuropathy. J Neurol 1980;224:17-23.
4. Dyck PJ, Lambert EH. Lower motor and primary sensory neuron diseases with peroneal muscular atrophy. II. Neurologic, genetic, and electrophysiologic findings in various neuronal degenerations. Arch Neurol 1968;18:619-625.
5. Dyck PJ, Lambert EH. Lower motor and primary sensory neuron diseases with peroneal muscular atrophy. I. Neurologic, genetic, and electrophysiologic findings in hereditary polyneuropathies. Arch Neurol 1968;18:603-618.
6. Shy ME, Garbern J, Kamholz J. Hereditary motor and sensory neuropathies: a biological perspective. Lancet Neurol 2002;1:110-118.
7. Krajewski KM, Lewis RA, Fuerst DR, et al. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 2000;123:1516-1527.
8. Sahenk Z, Chen L. Abnormalities in the axonal cytoskeleton induced by a connexin32 mutation in nerve xenografts. J Neurosci Res 1998;51:174-184.
9. Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. Neurology 1999;53:1660-1664.
10. Group UEC. The DASH Outcome Measure: user's manual. Toronto, Canada, 1999.
11. Cohen JA, Cutter GR, Fischer JS, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 2001;58:961-967.
12. Dyck PJ, Litchy WJ, Lehman KA, et al. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology 1995;45:1115-1121.
13. Dyck PJ, Sherman WR, Hallcher LM, et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 1980;8:590-596.
14. Kalkers NF, de Groot V, Lazeron RH, et al. MS functional composite: relation to disease phenotype and disability strata. Neurology 2000;54:1233-1239.
15. Sereda MW, Meyer Z, Horste G, Suter U, Uzma N, Nave KA. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 2003;9:1533-1537.
16. Passage E, Norreal J-C, Fraissignes PN, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot Marie Tooth disease. Nat Med 2004 (in press).